Recorded February 28, 2024
With Laura Nisenbaum, PhD and Phyllis Ferrell, DrPH, MBA
Most recently serving as Global Head of External Engagement for Alzheimer’s Disease at Eli Lilly & Company, Phyllis Ferrell has nearly 30 years of experience in the pharmaceutical industry and has played a key role in Lilly’s portfolio of Alzheimer’s therapeutics and diagnostic tools, as well as serving as a relentless advocate for patients and families living with the disease. She will join the Alzheimer’s Drug Discovery Foundation’s (ADDF) Executive Director of Drug Development, Dr. Laura Nisenbaum, in conversation to discuss the most promising recent advancements in Alzheimer’s therapies and the direction the field is headed in this new era of treatment possibilities. In addition to her nonprofit experience, Dr. Nisenbaum previously held roles at Biogen and Eli Lilly. The two industry and research professionals currently collaborate in their work on the ADDF’s Diagnostics Accelerator, a $100 million initiative focused on developing accessible tools to diagnose the disease earlier than ever, for which Ms. Ferrell serves as a strategic reviewer.
Presented by The Alzheimer’s Drug Discovery Foundation in partnership with Heidi and Tom McWilliams
Alzheimer’s Disease affects more than 50 million people and is the only top 10 cause of death that cannot yet be “prevented, treated or cured.” “Tomorrow’s Breakthroughs Today” features world-class scientists discussing the path toward new, cutting-edge treatments for Alzheimer’s and other dementias. This series invites three top investigators to share the latest updates on their research with moderator Dr. Howard Fillit, Co-Founder and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation (ADDF). Founded in 1998 by Leonard A. and Ronald S. Lauder, the ADDF is dedicated to developing therapeutics and biomarkers that prevent, treat, and cure Alzheimer’s and related dementias.
This event is sold out.